The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated×2•Originally published 5 May 2026•Updated 7 May 2026•

1 min read

Ocugen and Travere Therapeutics Announce Multi-Million Dollar Convertible Note Offerings

Key Facts

1Ocugen announced the pricing of a private offering of $115 million in 6.75% convertible senior notes due 2034.

2The company expects net proceeds of approximately $99.5 million after deducting expenses and discounts.

3The company granted the initial purchaser a 13-day option to purchase up to an additional $15 million in notes.

Ocugen, Inc. has priced a $115 million private offering of 6.75% convertible senior notes to retire high-interest debt and extend its cash runway through 2028. Joining this trend of debt optimization, Travere Therapeutics (TVTX) priced an upsized $475.0 million offering of 0.50% convertible senior notes due 2032. The aggregate principal for Travere was increased from the initially planned $400.0 million to $475.0 million due to strong interest, with proceeds earmarked to refinance existing notes due in 2029. Meanwhile, Disc Medicine continues to advance its clinical pipeline with the completion of enrollment for its Phase 3 APOLLO study. These strategic moves highlight a broader sector effort to replace expensive obligations with lower-coupon convertible instruments. Market participants are closely watching how these capital raises will support long-term clinical development and balance sheet stability.

28 days ago

Version History

Version 228 days ago

What changed: Added information regarding Travere Therapeutics pricing an upsized $475 million debt offering to refinance its existing obligations.

Version 129 days ago

What changed: Updated to include Ocugen's debt retirement plans, positive OCU410 clinical data, and extended cash runway projections, alongside Disc Medicine's Phase 3 enrollment milestone.